Category: HIV

2021 IPO & M&A Trends

By AGT | Feb 7, 2022

Contributing Author John Vandermosten, Senior Biotechnology Analyst Transaction Trends 2021: Pandora’s Box 2020 was a tremendous year for Initial Public Offerings (IPOs) where 494 new issues came to market[1], but the achievement was eclipsed in 2021 with an all-time record of 1,058 companies going public.  In healthcare/life sciences, we counted 118 IPOs in 2020, rising to an impressive 147 in 2021. … [Read More]

The Arc of HIV History 4

Chapter IV: Solving The Riddle, A Consequential Approach

By AGT | May 23, 2021

The arc of HIV history has been developing over the last four decades.  In the early days there was much we did not know, but as teams of physicians, researchers and patients increased their understanding of the disease, progress was made.  Early efforts with repurposed cancer drugs gave way to numerous viral inhibitor combinations.  On a parallel course, attempts to… [Read More]

The Berlin Patient’s Success Produces A Flurry of Activity

By AGT | Dec 30, 2020

The Berlin Patient’s Success Produces A Flurry of Activity With an important milestone in the rearview mirror and clarity on the course ahead, the Berlin patient’s success invigorated new efforts to eliminate the CCR5 receptor.  Stem cell replacement cannot be practiced widely because of its risk, complexity and requirement for a highly compatible donor.  Many patients who received bone marrow… [Read More]

Why Is It So Difficult to Find an HIV Cure?

By AGT | Oct 22, 2020

More than 32 million people have died from AIDS-related illnesses since the start of the epidemic in 1981, making HIV/AIDS one of the greatest public health threats the world has known. Since it was first identified nearly 40 years ago, trillions of dollars have been spent by governments and private individuals on efforts to find effective treatments, vaccines, and a… [Read More]

ARC of HIV History 2 – A Beginning and an End

By AGT | Oct 20, 2020

Contributing Author John Vandermosten, Senior Biotechnology Analyst This is the second installment of our series on the Arc of HIV History which examines the earliest emergence of HIV and the progress that has been made until today.  In Part 2 we look at the genesis of the first approved HIV drug and the first cure of HIV in the Berlin Patient…. [Read More]

In Memory of Timothy Ray Brown

By AGT | Oct 2, 2020

A Message From the CEO of American Gene Technologies® Timothy Ray Brown – March 11, 1966 – September 29, 2020 Timothy Ray Brown was both a person and a turning point in the arc of HIV history. Timothy received a bone marrow transplant and became functionally cured; a symbol to the world that a cure for HIV was possible. He… [Read More]

AGT Announces First-Ever Reddit AMA on the Potential of Gene Therapies

By AGT | Apr 21, 2016

We are proud to have participated in our first-ever Reddit AMA on April 21, 2016. AGT CEO, Jeff Galvin and Chief Science Officer, Dr. David Pauza discussed the future of gene therapy and viral vectors as a delivery vehicle.   See the full Reddit AMA HERE

Subscribe to Our Newsletter

Subscribe to our newsletter to keep up to date with all the latest news about AGT!

Mailchimp sidebar

Follow AGT on Social Media